Skip to main content

RS BioTherapeutics, Inc.

October 17, 2023
Franciscan B
Infectious Diseases
Company Description: RS BioTherapeutics (RSBT) is developing a pharmaceutical compound for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other diseases characterized by pulmonary inflammation. RSBT-001 harnesses the immune modulating power of specific, anti-inflammatory and non-intoxicating cannabinoids delivered by a proprietary, polarity adaptive transport mechanism and reduces pulmonary inflammation by targeting the inflammatory cascade in the lungs at multiple levels. RSBT is currently engaged with NIH in a Research Collaboration Agreement (RCA) to evaluate RSBT-001 in the prevention and treatment of IPF.
Dean Hart, CEO - RS BioTherapeutics, Inc.